

# BUDGET FACT BOOK

FOR FISCAL YEAR

# 2020



# TABLE OF CONTENTS

<b>3</b>	<b>NCI BUDGET FACT BOOK</b>
<b>6</b>	<b>NCI BUDGET SUMMARY DATA</b>
6	Most Recent Reported Fiscal Year Budget
7	Funding Allocated to Major NCI Program Areas
8	Extramural Funding
10	Obligations by Budget Mechanism and Division
29	NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent
32	Special Sources of Funds
37	Funding for Research Areas
<b>39</b>	<b>NCI EXTRAMURAL PROGRAMS</b>
39	Research Project Grants (RPGs)
49	Grants to NCI-Designated Cancer Centers
57	Specialized Programs of Research Excellence (SPOREs)
60	National Research Service Awards (NRSA)
61	Research Career Awards “K” Program
63	Grant and Contract Awards
<b>67</b>	<b>NCI HISTORICAL TRENDS</b>
67	Bypass Budget Requests and NCI Appropriations
72	NCI Funding Trends
75	Extramural vs Intramural and RMS Funding
78	Comparison of Dollars, Positions, and Space
79	NCI Personnel
80	NCI and NIH AIDS Funding History
<b>81</b>	<b>CANCER MOONSHOT<sup>SM</sup> - RECENT FISCAL YEAR FUNDING</b>
82	Obligations by Budget Mechanism
85	Funding by Research Category

# NCI Budget Fact Book

This report provides a summary of the distribution of the Fiscal Year 2020 budget among the various National Cancer Institute (NCI) research programs and funding mechanisms, funding policies influencing grant awards, and comparisons with prior year allocations.&

## FISCAL YEAR 2020 HIGHLIGHTS

Funds available to the NCI totaled \$6.25 billion, post inter-departmental and intra-NIH transfers, including \$50 million for the Childhood Cancer Data Initiative and \$25 million for Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act. This reflects an increase of 9.2% and \$524.2 million from the previous fiscal year.&

Fiscal year highlights include:

- The Childhood Cancer Data Initiative (CCDI) will facilitate a connected data infrastructure and integrate multiple data sources to make data work better for patients, clinicians, and researchers.
- The Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act, which was signed into law in June 2018, authorized funds for NCI to expand existing biorepositories for childhood cancer patients enrolled in NCI-sponsored clinical trials to collect and maintain relevant clinical, biological, and demographic information on children, adolescents, and young adults, and to continue to conduct and support pediatric cancer survivorship research.
- The 21st Century Cures Act, which was signed into law in December 2016, authorized \$1.8 billion to fund the Cancer Moonshot over a 7-year period. The Cancer Moonshot funding received during Fiscal Year 2020 totaled \$195 million.
- The Paycheck Protection Program and Health Care Enhancement Act authorized \$306,000,000 for serological testing in support of NIH's research during the COVID-19 pandemic.
- Of the total NCI budget obligated, 43.1% of the funds were allocated for Research Project Grants (RPGs).
- The total number of RPGs funded was 5,070 (including grants funded through the Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) programs).
- Over one-fourth of the RPGs awarded were new ("Type 1") or competing renewal ("Type 2") awards.
- There was a total of 1,217 competing RPGs funded (excluding grants funded through SBIR & STTR).
- Almost one-third of the total NCI budget supported ongoing, non-competing ("Type 5") RPGs.

## FISCAL YEAR 2020 HIGHLIGHTS (CONTINUED)

- The R01 grants were funded to the 10th percentile for Experienced and New Investigators and the Early Stage Investigators were funded to the 15th percentile.
- R01 Early Stage Investigators between the 1st and 10th percentiles were converted to R37 awards giving them the opportunity to extend their research an additional 2 years.
- SBIR & STTR awards funded 217 grants totaling \$151.1 million.
- Intramural Research comprised 16.8% of the total NCI budget.&


The dollar amounts displayed in the NCI Budget Fact Book represent direct appropriated funds only, unless otherwise denoted.

## Where to Find Information from Previous Fact Books

Information provided in previous Fact Books can now be found online. For example, view NCI's Organization Chart on the NIH Office of Management Assessment website. Cancer statistics can be found on the NCI website, as well as more detailed NCI Organization information. A limited number of Fact Books from prior years are available as hardcopy publications through the NCI Publications Locator. Find PDFs of all the NCI Budget Fact Books, dating back to 1971.

The NCI Budget Fact Book data is organized into the following sections. If you have any questions, please contact the Office of Budget and Finance (OBF).&

## Budget At A Glance: Fiscal Year 2020



NCI BUDGET INCREASED BY **\$524.2 MILLION** (9.2%) FROM FISCAL YEAR 2019

**43.1%** OF THE TOTAL NCI BUDGET ALLOCATED FOR RESEARCH PROJECT GRANTS

THE NATIONAL CANCER INSTITUTE (NCI) PROVIDES FUNDING AND SUPPORT FOR HEALTH-RELATED RESEARCH AND DEVELOPMENT THROUGH THE RPG (R01) GRANT MECHANISM.



R01 EARLY STAGE INVESTIGATORS BETWEEN THE 1<sup>ST</sup> AND 10<sup>TH</sup> PERCENTILES WERE CONVERTED TO R37 AWARDS GIVING THEM THE OPPORTUNITY TO EXTEND THEIR RESEARCH AN ADDITIONAL 2 YEARS.



OF RPG AWARDS WERE NEW (TYPE 1) OR COMPETING RENEWAL (TYPE 2) AWARDS



OF THE TOTAL NCI BUDGET SUPPORTED ONGOING, NON-COMPETING (TYPE 5) RPGs

**1,217** NCI-FUNDED COMPETING RPGs



TOTALING OVER \$151.1 MILLION FUNDED AS SMALL BUSINESS INNOVATION RESEARCH (SBIR) AND SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) AWARDS.

**4,984** TOTAL NCI-FUNDED RPGs (INCLUDING SBIR & STTR)

# NCI Budget Summary Data

This section provides detailed data about funds available to NCI and information on how NCI obligated its funding.

## Most Recent Reported Fiscal Year Budget

In FY 2020, Congress passed a consolidated appropriations act allocating \$6.245 billion to NCI, including \$50 million for the Childhood Cancer Data Initiative (CCDI) and \$25 million for Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act. NCI was also appropriated \$195 million in FY 2020 as a result of the 21st Century Cures Act. After permissive transfers, \$6.440 billion was available to NCI to obligate.

In addition to the appropriated amount for the fiscal year, NCI entered into inter- and intra-agency agreements with other Federal agencies and NIH institutes and centers (ICs). These agreements often provide reimbursements for materials, supplies, equipment, work, or services to assist other agencies and ICs accomplish their missions.

## FISCAL YEAR 2020 BUDGET

*(Whole Dollars)*

Actual Obligations Resulting From Appropriated Funds	FY 2019 Amount
FY 2020 Appropriation	\$6,245,442,000
FY 2020 Cancer Moonshot Appropriation	\$195,000,000
Transfer from NIH Office of AIDS Research	-\$4,000
Lapse	-\$254,618
Cancer Moonshot Carryover	-\$56,834,471
Actual Obligations Subtotal	\$6,383,348,911
<b>Reimbursable Obligations</b>	<b>\$21,356,275</b>
<b>Total FY 2020 NCI Obligations</b>	<b>\$6,404,705,186</b>
<b>Total FY 2019 NCI Obligations</b>	<b>\$5,992,289,909</b>

## Funding Allocated to Major NCI Program Areas


Each fiscal year, NCI and other NIH institutes and centers report their obligations by mechanism. In addition to reporting by mechanism, reporting obligations by program structure is another way of showing how NCI obligates its funding each fiscal year.&

For the purposes of reporting by program structure, NCI programs are categorized by budget activity. These budget activities include:

- Research – categorized by the following research thrusts: Childhood Cancer Data Initiative (CCDI), cancer causation; detection and diagnosis; treatment; and cancer biology
- Resource Development – cancer centers, research manpower development, and buildings and facilities
- Cancer Prevention and Control
- Program Management and Support

### Program Structure

Fiscal Year 2020



cancer.gov

*\*Includes FY 2020 Cures Moonshot funding and excludes FYs 2019 through 2017 Cures Moonshot carryover obligations.*

## Extramural Funding


Overall, NCI obligations for its extramural program, which includes grants and contracts, totaled \$4.86 billion in FY 2020.

- Obligations for grants totaled approximately 82.5% of extramural funding&
- Obligations for contracts totaled approximately 17.5% of extramural funding&

Obligations on this page include FY 2020 Cancer Moonshot funding and excludes fiscal years 2017 through 2019 Cures Moonshot carryover obligations.

### Extramural Funds

Fiscal Year 2020



cancer.gov



## EXTRAMURAL FUNDS, FISCAL YEAR 2020

(Whole Dollars)

Mechanism	Amount	Percent
Research & Development (R&D) Contracts	\$823,012,066	16.9%&
Buildings and Facilities	30,000,000	0.6%&
Construction Contracts	0	0.0%&
<b>Subtotal Contracts</b>	<b>\$853,012,066</b>	<b>17.5%</b>
Research Project Grants (RPGs)	2,749,367,903	56.6%&
Cancer Centers/Specialized Centers/SPORES	613,771,451	12.6%&
NRSA	96,424,956	2.0%&
Other Research Grants	548,133,685	11.3%&
<b>Subtotal Grants</b>	<b>\$4,007,697,995</b>	<b>82.5%</b>
<b>Total Extramural Funds</b>	<b>\$4,860,710,061</b>	<b>100.0%</b>
<i>Intramural/RMS Funds</i>		<i>1,522,638,850</i>
<b>Total NCI</b>		<b>\$6,383,348,911</b>


## Obligations by Budget Mechanism and Division

All NIH Institutes and Centers report their actual obligations each fiscal year by budget mechanism. The tables below display NCI funding by mechanism and division. The number of awards, trainees, or employees for each mechanism, as well as the dollar amount and percent share of the total NCI budget for each funding mechanism is also included.

### NCI Obligations by Mechanism

## Percent Share of Total NCI Dollars

### Fiscal Year 2020



cancer.gov

Other Research mechanisms includes the following grants: Career Programs (K Awards), Cancer Education, Clinical Cooperative Groups, Pre-Doc Post-Doc Transition Awards, Education Projects - Cooperative Agreements, Minority Biomedical Research Support, Research Pathway in Residency, Pilot Research Project, Resource Grants, International Research Training grants, Cooperative Conference Agreements, Conference grants, and Other Transaction Authority (OTA).

All items in italics are non add entries.

*\*Includes FY 2020 Cures-Moonshot funding.*

*\*Excludes FY 2019, FY 2018, and FY 2017 Cures-Moonshot carryover obligations.*

## NCI OBLIGATIONS

NCI Obligations by Mechanism, FY 2020

(Whole Dollars)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Research Project Grants (RPGs)	Non-Competing	3,631	\$1,905,787,328	29.9%
	Administrative Supplements	219	30,211,732	0.5%
	Competing	1,204	662,228,214	10.4%
	<b>Subtotal, without SBIR/STTR Grants</b>	<b>4,835</b>	<b>\$2,598,227,274</b>	<b>40.7%</b>
	SBIR/STTR Grants	217	151,140,629	2.4%
	<b>Subtotal, RPGs</b>	<b>5,052</b>	<b>2,749,367,903</b>	<b>43.1%</b>
Centers & SPOREs	Cancer Centers Grants-P20/P30	93	381,955,514	6.0%
	SPOREs	50	113,177,200	1.8%
	Other P50s/P20s	9	7,942,623	0.1%
	Other Specialized Centers	94	110,696,114	1.7%
	<b>Subtotal, Centers</b>	<b>246</b>	<b>\$613,771,451</b>	<b>9.6%</b>
Other Research	Career Program			0.0%
	Post-Doc-Fellow Awards-K00	68	6,019,542	0.1%

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Other Research	Temin & Minority Mentored Awards-K01/K43	31	5,450,807	0.1%&
	Estab. Inv. Award-K-05	0	0	0.0%&
	Preventive Oncology-K07	46	7,296,818	0.1%&
	Clinical Investigator-K08	192	41,376,183	0.6%&
	Clinical Oncology-K12	21	15,968,136	0.3%&
	Transitional Career Development-K22	51	9,340,487	0.1%&
	Mentored Patient Oriented RCDA-K23	7	1,179,584	0.0%&
	Mid-Career Invest. & Patient Orient. Res-K24	5	822,239	0.0%&
	Mentored Quant. Res Career-K25	3	425,733	0.0%&
	Mentored Career Devel/Tem Intl Career-K43	0	290,482	0.0%&
Pathway to Independence Awards K99	63	8,408,294	0.1%&	

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
	<b>Subtotal, Career Program</b>	<b>487</b>	<b>\$96,578,305</b>	<b>1.5%</b>
Other Research	Cancer Education Program-R25 (including BD2K)	9	14,877,672	0.2%&
	Clinical Cooperative Groups-U10/UG1	106	295,621,973	4.6%&
	PreDoc PostDoc Transition Awards-F99	48	1,959,966	0.0%&
	UE5 Education Projects	5	1,998,370	0.0%&
	Minority Biomedical Support-S06	0	97,866	0.0%&
	Research Pathway in Residency (R38)	2	713,828	0.0%&
	Pilot Research Project-OT2	0	77,139	0.0%&
	Resource Grants-R24/U24/U2C	93	134,541,158	2.1%&
	Cooperative Conference Agreements - U13/R13	46	663,753	0.0%&

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Other Research	Int'l Research Training Grants Conference- D43/ U2R	0	1,003,655	0.0%&
	<b>Subtotal, Career and Other Research Grants</b>	<b>846</b>	<b>\$548,133,685</b>	<b>8.6%</b>
<b>Subtotal, Research Grants</b>		<b>6,144</b>	<b>\$3,911,273,039</b>	<b>61.3%</b>
National Research Service Award (NRSA) Fellowships	Trainees	1,693	96,424,956	1.5%&
R&D Contracts	R&D Contracts	348	684,898,306	10.7%&
	SBIR Contracts	47	23,955,859	0.4%&
	NIH Management Fund/SSF Assessment		114,157,901	1.8%&
	<b>Subtotal, Contracts</b>	<b>395</b>	<b>\$823,012,066</b>	<b>12.9%</b>
Intramural Research	Program		823,065,394	12.9%&
	NIH Management Fund/SSF Assessment		249,537,006	3.9%&
	<b>Subtotal, Intramural Research (FTEs)</b>	<b>1,755</b>	<b>\$1,072,602,400</b>	<b>16.8%</b>

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Research Management & Support (RMS)	Research Management and Support (RMS)		342,523,328	5.4%&
	SBIR RMS		2,892,985	0.
Research Management & Support (RMS)	NIH Management Fund/SSF Assessment		104,620,137	1.6%&
	<b>Subtotal, RMS (FTEs)</b>	<b>1,238</b>	<b>\$450,036,450</b>	<b>7.1%</b>
Buildings & Facilities			30,000,000	0.5%&
<b>Total NCI</b>	<b>(FTEs)</b>	<b>2,993</b>	<b>\$6,383,348,911</b>	<b>100.0%</b>

# Division Obligations by Mechanism

## DIVISION OBLIGATIONS

Total Division Obligations, FY 2020

(Whole Dollars)

Division	Total
Center for Cancer Research (CCR)	\$495,408,641
Division of Cancer Epidemiology and Genetics (DCEG)	120,771,583
Division of Cancer Treatment and Diagnosis (DCTD)	572,736,223
Division of Cancer Biology (DCB)	58,319,589
Division of Cancer Control and Population Sciences (DCCPS)	140,222,622
Division of Cancer Prevention (DCP)	226,755,029
Division of Extramural Activities (DEA)	20,227,259
Office of the Director (OD)	1,681,674,009
<b>Total Division</b>	<b>\$5,916,460,342</b>

## CENTER FOR CANCER RESEARCH (CCR)

CCR Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Intramural Research	Program	\$495,408,641
	NIH Management Fund	0
<b>Total CCR</b>		<b>\$495,408,641</b>



## DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS (DCEG)

### DCEG Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
R&D Contracts	R&D Contracts	\$34,634,497
	SBIR Contracts	0
Intramural Research	Program	86,137,086
	NIH Management Fund	0
<b>Total DCEG</b>		<b>\$120,771,583</b>

## DIVISION OF CANCER TREATMENT AND DIAGNOSIS (DCTD)

### DCTD Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPORES	Cancer Centers Grants-P20/ P30	\$315,259
	SPORES-P50	112,566,805
	Other P50s/P20s	351,000
	Other Specialized Centers	9,715,582
	<b>Subtotal, Centers</b>	<b>\$122,948,646</b>
Other Research-Grants	Cancer Education Program-R25	0
	Clinical Cooperative Groups-U10/UG1	152,303,774

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research–Grants	PreDoc PostDoc Transition Awards-F99	0
	UE5 Education Projects	0
	Minority Biomedical Support-S06	0
	Rsrch Pathway in Residency (R38)	0
	Pilot Research Project-OT2	0
	Resource Grants-R24/U24	6,621,330
	Cooperative Conference Agreements-U13/R13	0
	Int'l Research Training Grants-D43/U2R	0
	<b>Subtotal, Other Research-Grants</b>	<b>\$158,925,104</b>
<b>Subtotal, Research Grants</b>		<b>\$281,873,750</b>
R&D Contracts	R&D Contracts	233,391,367
	SBIR Contracts	0
	NIH Management Fund/SSF Assessment	0
	<b>Subtotal, Contracts</b>	<b>\$233,391,367</b>

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Research Management & Support (RMS)	RMS	57,471,106
	SBIR RMS	0
	NIH Management Fund/SSF Assessment	0
	<b>Subtotal, RMS</b>	<b>\$55,292,457</b>
<b>Total DCTD</b>		<b>\$572,736,223</b>

## DIVISION OF CANCER BIOLOGY (DCB)

### DCB Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/ P30	\$0
	SPOREs-P50	0
	Other P50s/P20s	178,097
	Other Specialized Centers	39,426,695
	<b>Subtotal, Centers</b>	<b>\$39,604,792</b>
R&D Contracts	R&D Contracts	0
	SBIR Contracts	0
	NIH Management Fund/SSF Assessment	0
	<b>Subtotal, Contracts</b>	<b>\$0</b>
Other Research-Grants	<b>Subtotal, Other Research- Grants</b>	<b>\$7,036,196</b>
Research Management & Support (RMS)	RMS	11,678,601
	SBIR RMS	0
	NIH Management Fund	0
	<b>Subtotal, RMS</b>	<b>\$11,678,601</b>
<b>Total DCB</b>		<b>\$58,319,589</b>

## DIVISION OF CANCER CONTROL AND POPULATION SCIENCES (DCCPS)

### DCCPS Obligations

Type of Mechanism	Mechanism	Amount
Centers & SPORES	Cancer Centers Grants-P20/ P30	\$0
	SPORES-P50	0
	Other P50s/P20s	7,413,526
	Other Specialized Centers	400,000
	<b>Subtotal, Centers</b>	<b>\$7,813,525</b>
	Cancer Education Program-R25 (including BD2K)	0
	Clinical Cooperative Groups-U10/UG1	0
	PreDoc PostDoc Transition Awards-F99	0
	UE5 Education Projects	0
	Minority Biomedical Support-S06	0
	Research Pathway in Residency (R38)	0
	Pilot Research Project-OT2	0
	Resource Grants-R24/U24/ U2C	7,707,073
	Cooperative Conference Agreements-U13/R13	0

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Int'l Research Training Grants-D43/U2R	0
	<b>Subtotal, Other Research Grants</b>	<b>\$7,707,073</b>
	<b>Subtotal, Research Grants</b>	<b>\$15,520,599</b>
R&D Contracts	R&D Contracts	88,225,622
	SBIR Contracts	0
	<b>Subtotal, Contracts</b>	<b>\$88,225,622</b>
Research Management & Support (RMS)	RMS	36,476,401
	SBIR RMS	0
	NIH Management Fund	0
	<b>Subtotal, RMS</b>	<b>\$36,476,401</b>
<b>Total DCCPS</b>		<b>\$140,222,622</b>

## DIVISION OF CANCER PREVENTION (DCP)

### DCP Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/ P30	\$0
	SPOREs-P50	0
	Other P50s/P20s	0
	Other Specialized Centers	7,375,200
	<b>Subtotal, Centers</b>	<b>\$7,375,200</b>
Other Research–Grants	Cancer Education Program-R25	0
	Clinical Cooperative Groups-U10/UG1	135,320,592
	PreDoc PostDoc Transition Awards-F99	0
	UE5 Education Projects	0
	Minority Biomedical Support-S06	0
	Rsrch pathway in Residency (R38)	0
	Pilot Research Project-OT2	0
	Resource Grants-R24/U24	974,841
	Cooperative Conference Agreements - U13/R13	0
	Int'l Research Training Grants-D43/U2R	0

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
	<b>Subtotal, Other Research Grants</b>	<b>\$136,295,433</b>
<b>Subtotal, Research Grants</b>		<b>\$143,670,633</b>
R&D Contracts	R&D Contracts	57,556,575
	SBIR Contracts	0
	NIH Management Fund/SSF Assessment	0
	<b>Subtotal, Contracts</b>	<b>\$57,556,575</b>
Research Management & Support (RMS)	RMS	25,527,821
	SBIR RMS	0
	NIH Management Fund/SSF Assessment	0
	<b>Subtotal, RMS</b>	<b>\$25,527,821</b>
<b>Total DCP</b>		<b>\$226,755,029</b>



## DIVISION OF EXTRAMURAL ACTIVITIES (DEA)

### DEA Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Research Management & Support (RMS)	RMS	\$20,227,259
	SBIR RMS	0
	NIH Management Fund	0
<b>Total DEA</b>		<b>\$20,227,259</b>

## OFFICE OF THE DIRECTOR (OD)

### OD Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount	
Research Project Grants (RPGs)	Non-Competing	\$0	
	Administrative Supplements	0	
	Competing	0	
	<b>Subtotal, without SBIR/ STTR Grants</b>		<b>\$0</b>
	SBIR/STTR Grants-R41 -44	151,140,629	
	<b>Subtotal, RPGs</b>		<b>\$151,140,629</b>

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/ P30	381,640,255
	SPOREs	610,395
	Other P50s/P20s	0
	Other Specialized Centers	53,284,677
	<b>Subtotal, Centers</b>	<b>\$435,535,327</b>
Other Research–Career Program	Career Program	0
	Post-Doc-Fellow Awards-K00	6,019,542
	Temin & Minority Mentored Awards-K01	5,450,807
	Estab. Inv. Award-K05	0
	Preventive Oncology-K07	7,296,818
	Clinical Investigator-K08	41,376,183
	Clinical Oncology-K12	15,968,136
	Transitional Career Development-K22	9,340,487
	Mentored Patient Oriented RCDA-K23	1,179,584
	Mid-Career Invest. & Patient Orient. Res-K24	822,239
	Mentored Quant. Res Career-K25	425,733

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research–Career Program	Mentored Career Devel/Tem Intl Career-K43	290,482
	Pathway Award-K99	8,408,294
	<b>Subtotal, Career Program</b>	<b>\$96,578,305</b>
Other Research–Grants	Cancer Education Program - R25 (including BD2K)	14,877,672
	Clinical Cooperative Groups-U10/UG1	7,997,607
	PreDoc PostDoc Transition Awards-F99	1,959,966
	UE5 Education Projects	1,998,370
	Minority Biomedical Support-S06	97,866
	Rsrch Pathway in Residency (R38)	713,828
	Pilot Research Project-OT2	77,139
	Resource Grants-R24/U24/U2C	112,201,718
	Cooperative Conference Agreements-U13/R13	663,753
	Int'l Research Training Grants-D43/U2R	1,003,655
	<b>Subtotal, Other Research–Grants</b>	<b>\$141,591,574</b>
<b>Subtotal, Research Grants</b>		<b>\$824,845,835</b>

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
NRSA Fellowships		96,227,278
R&D Contracts	R&D Contracts	271,090,245
	SBIR Contracts	23,955,859
	NIH Management Fund/ SSF Assessment/Program Evaluation	0
	<b>Subtotal, Contracts</b>	<b>\$295,046,104</b>
Intramural Research	Program	241,519,667
	NIH Management Fund/ SSF Assessment/Program Evaluation	0
	<b>Subtotal, Intramural Research</b>	<b>\$241,519,667</b>
Research Management & Support (RMS)	RMS	191,142,140
	SBIR RMS	2,892,985
Research Management & Support (RMS)	NIH Management Fund/ SSF Assessment/Program Evaluation	0
	<b>Subtotal, RMS</b>	<b>\$194,035,125</b>
Buildings and Facilities		30,000,000
<b>Total OD</b>		<b>\$1,681,674,009</b>

## NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

**Clinical Center:** Admissions and follow-up, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition services, housekeeping services, laundry, social work, drug costs, red team response, bench to bedside and the Children's Hospital.

**Center for Scientific Review:** Initial scientific review of applications and assignment of research grant applications to institutes.


**Center for Information Technology:** Research and development program in which concepts and methods of computer science are applied to biomedical problems.

**Other Research Services:** Procurement, safety, engineering, biomedical engineering, veterinary resources, and library services.

**Service & Supply Fund:** Mainframe computing, enterprise IT software planning and development, engineering planning and design, printing, telecommunications, procurement, shipping and receiving, motor pool, research animals, fabrication and maintenance of scientific equipment, utilities and plant maintenance, biomedical engineering, background investigations, IT cybersecurity and GSA rental payments for space (to include all building rental costs, including utilities and guard services).

# NIH Management Fund, Service & Supply Fund and GSA Rent

Fiscal Year 2020



cancer.gov

*\*Figures include additional costs incurred due to the 2020 Coronavirus Pandemic (COVID-19).*

## NIH MANAGEMENT FUND, SSF, AND GSA RENT FY 2020

(Whole Dollars)

Distribution of NCI Payment	Amount	Share of NCI
Clinical Center	\$153,676,485	37.7%&
Center for Scientific Review	22,969,143	5.6%&
Center for Information Technology	33,534,007	8.2%&
Service & Supply Fund Assessment (SSF)	184,918,145	45.3%&
Other Research Services	12,923,630	3.2%&
Other OD	0	0.0%&
<b>Total NCI Management Fund &amp; SSF</b>	<b>\$408,021,409</b>	<b>100%</b>

## NIH FY 2020 MANAGEMENT FUND & SSF

(Whole Dollars)

Type	Amount	Percent
NCI	\$408,021,409	19.7%&
Other NIH Institutes	\$1,667,584,649	80.3%&
<b>Total NIH Management Fund &amp; SSF</b>	<b>\$2,075,606,058</b>	<b>100%</b>

## Special Sources of Funds

### Cooperative Research and Development Agreements (CRADAs)

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Under a CRADA, the NIH laboratory can provide personnel, services, facilities, equipment or other resources and the collaborator can provide funds, personnel, services, facilities, equipment or other material and/or technical resources. Importantly, the CRADA provides the non-Federal party the option to negotiate an exclusive license to the resultant CRADA Subject Invention(s). The CRADA is the primary legal mechanism the Federal government has to convey such rights in advance of an invention. The agreement has no mandatory length but often are written for 1 to 3 years, renewable at the mutual agreement of the parties.

### CRADA RECEIPTS DEPOSITED TO THE U.S. TREASURY

*(Dollars in Thousands)*

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2006	13,567	6,142	7,125
2007	12,584	9,410	8,360
2008	13,634	6,677	7,200
2009	13,111	5,466	4,765
2010	13,813	5,024	5,644
2011	13,150	8,582	5,894
2012	15,504	9,253	5,668
2013	10,587	11,226	8,470
2014	21,173	9,334	5,672
2015	24,835	15,772	11,670
2016	28,276	23,411	17,259



(Continued from previous page)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2017	40,647	27,033	20,990
2018	46,311	28,601	22,936
2019	50,978	32,899	28,178
2020	53,825	33,776	28,683

## Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to support employees of the laboratory, further scientific exchange, and provide education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts at NCI and NIH. Royalties may be spent in the year of receipt and for two additional fiscal years.

## NCI ROYALTY INCOME FUNDING HISTORY

(Dollars in Thousands)

Years	Collections*	Inventor Payments	Other Obligations
2006/2008	29,811	6,853	22,958
2007/2009	36,344	7,210	29,134
2008/2010	50,269	8,192	42,077
2009/2011	51,621	10,225	41,396
2010/2012	58,515	5,729	52,786
2011/2013	69,155	23,271	45,884
2012/2014	84,876	33,279	51,597

(Continued from previous page)

Years	Collections*	Inventor Payments	Other Obligations
2013/2015	91,324	48,433	42,891
2014/2016	112,668	33,487	79,181
2015/2017	122,037	30,605	91,432
2016/2018	115,096	27,316	87,780
2017/2019	112,611	27,233	85,378
2018/2020	86,231	15,539	70,692
**2019/2021	70,400	10,000	60,400
**2020/2022	30,850	10,000	20,850

\* Collections do not include assessments by NIH.

\*\* 2019/2021 and 2020/2022 Inventor Payments and Other Obligations are estimates.

## Stamp Out Breast Cancer Act

The Stamp Out Breast Cancer Act (PL 105-41) was enacted in August 1997 and has since been extended to July 2000 (PL 106-253), November 2005 (PL 109-100), December 2007 (PL 110-150), December 2011 (PL 112-80), December 2015 (PL 114-99) and recently until December 2027 (PL 116-92). This act allows postal customers the opportunity to contribute funds to breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service (USPS). Of the funds collected above the postage costs and administrative costs, the Act requires the USPS to transfer 70% to NIH and 30% to the Department of Defense. As of September 2020, NCI has received \$63,225,028. NCI uses these funds for research projects directed towards breast cancer research. Thus far, five major programs have been funded, including the Insight Awards to Stamp Out Breast Cancer, the Breast Cancer Research Stamp Exceptional Opportunities Program, the Breast Cancer Premalignancy Program, a clinical trial to determine the risk of breast cancer recurrence, the Molecular and Cellular Characterization of Screen Detected Lesions Consortium, the Breast Cancer Weight Loss (BWEL), and the Tomosynthesis Mammographic Imaging Screening Trial (TMIST). In FY 2020, \$2,570,651 million in Stamp funds were obligated towards Breast Cancer research.

### NCI BREAST CANCER STAMP FUNDING HISTORY

(Dollars in Thousands)

FY	Collected	Obligated	*Balance
1999	4,150	0	4,150
2000	3,101	3,499	3,753
2001	5,556	4,846	4,463
2002	3,595	1,129	6,929
2003	5,176	3,130	8,975
2004	4,814	3,472	10,317
2005	4,372	2,987	11,703
2006	4,468	6,896	9,274
2007	3,006	1,601	10,679

(Continued from previous page)

FY	Collected	Obligated	*Balance
2008	4,856	2,122	13,413
2009	3,403	1,873	14,944
2010	2,345	2,590	14,698
2011	2,049	1,977	14,770
2012	1,623	1,654	14,738
2013	1,404	1,337	14,805
2014	1,160	1,477	14,488
2015	1,251	1,635	14,105
2016	1,707	1,654	14,158
2017	1,387	1,640	13,905
2018	1,294	5,349	16,497
2019	1,450	2,518	15,429
2020	1,060	2,571	13,918

**\*Balance includes carryover funds from the prior fiscal year that have not obligated.&**

## Funding for Research Areas

The National Cancer Institute reports how appropriated funds are spent based on different categories or classifications, including specific cancer sites, cancer types, diseases related to cancer, as well as types of NCI research mechanisms. The table below identifies funding levels for frequently requested areas of cancer research.

The research areas in this table do not represent the entire NCI research portfolio. Moreover, funding for research areas often overlap, and therefore the total for all research areas does not add to the total NCI budget. For example, funding for a clinical trial on breast cancer would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine, and ovarian cancers, and relevant amounts would be included in the amounts for all three areas of cancer research.

### FUNDING BY RESEARCH AREAS

(Dollars in Millions)

Disease Area	2014 Actual	2015 Actual	2016 Actual	2017 Actual	2018 Actual	2019 Estimate
<b>Total NCI Budget</b>	<b>\$4,932.4</b>	<b>\$4,952.6</b>	<b>\$5,206.2</b>	<b>\$5,636.4</b>	<b>\$5,927.7</b>	<b>\$6,440.4</b>
AIDS	269.2	269.7	266.4	249.0	241.2	242.0
Brain & CNS	180.4	204.8	196.3	219.8	220.9	231.7
Breast Cancer	528.5	543.6	519.9	544.9	574.9	545.4
Cervical Cancer	71.1	57.1	65.6	68.8	71.5	86.0
Clinical Trials	749.8	748.0	801.0	806.6	895.7	794.3
Colorectal Cancer	223.0	209.3	212.2	208.4	256.0	238.8
Head & Neck Cancers	57.1	60.2	58.9	46.4	62.4	117.1
Hodgkin Disease	15.4	13.6	12.8	13.0	13.3	12.2
Leukemia	236.7	246.9	241.0	250.5	258.3	256.6

(Continued from previous page)

Disease Area	2014 Actual	2015 Actual	2016 Actual	2017 Actual	2018 Actual	2019 Estimate
Liver Cancer	60.0	70.3	75.7	72.7	95.9	107.8
Lung Cancer	254.1	255.8	283.8	320.6	350.1	418.8
Melanoma	126.2	132.8	142.9	153.2	158.4	191.9
Multiple Myeloma	46.6	48.9	52.1	60.7	61.5	58.2
Non-Hodgkin Lymphoma	118.0	122.4	116.7	119.5	121.0	120.4
Ovarian Cancer	91.5	92.8	95.6	110.1	120.8	121.5
Pancreatic Cancer	122.4	125.3	152.6	178.3	182.1	187.0
Prostate Cancer	217.8	228.9	241.0	233.0	239.3	244.8
Stomach Cancer	11.3	13.5	13.3	13.4	14.2	14.8
Uterine Cancer	15.5	13.0	16.8	17.5	17.5	18.0

These figures were created using NCI’s coding methodology. More information about this methodology, as well as the research projects associated with these and other disease area categories, are available on the [NCI Funded Research Portfolio](#) website.

The FY 2019 funds available to the NCI totaled \$6.1 billion (includes \$400 million in CURES Act funding), reflecting an increase of 3 percent, or \$178 million from the previous fiscal year. Under the NCI RPG funding policy for FY 2019, non-competing grants were awarded with a 3 percent reduction from the committed level. For more information on NCI’s grant funding policy, visit the [NCI Division of Extramural Activities](#) website.

# NCI Extramural Programs

The NCI uses most of its budget to fund extramural grants and contracts. The following links provide information about Fiscal Year 2018 extramural funding by grant activity, institution, state, and country.

## Research Project Grants (RPGs)

During fiscal year 2020,&

- Over 76% of competing dollars supported grants awarded within the established payline and RFAs and the remainder supported grants as an exception to the fundable range.
- RFA funds accounted for 21% of the FY 2020 competing dollars.&
- A total of 1,217 competing RPGs were funded.

The FY 2019 figures include FY 2019 Cancer Moonshot funds and the FY 2020 figures include FY 2020 Cancer Moonshot funds.

The FY 2020 competing RPG average cost calculation includes multi-year funded grants with a 1 year average cost estimation.

## Number of RPG Awards



*\*Includes Small Business Innovation Research and Small Business Technology Transfer Awards. Fiscal years 2017, 2018, 2019, and 2020 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.*

## RPGs Summary, FY 2019-2020

### RPG AWARDS FUNDED

(Dollars in Thousands)

RPG Awards Funded	2019 No. or %	2019 Amount	2020 No. or %	2020 Amount
<b>Total Funding for RPGs</b>	<b>4,984</b>	<b>2,541,700</b>	<b>5,070</b>	<b>2,771,666</b>
SBIR/STTR	245	136,670	217	151,141
Funding for RPGs without SBIR/STTR Program	4,739	2,405,030	4,853	2,620,526
Continuation or Noncompeting Grants Funded	3,561	1,716,055	3,636	1,814,161
Competing Grants Funded	1,178	572,716	1,217	681,401
Administrative Supplements	268	30,715	221	30,503
Partial Assessment for DHHS Program Evaluation		85,543		94,460

### FUNDS SET ASIDE WITHIN COMPETING DOLLARS

(Dollars in Thousands)

Grant Category	R01 or Share	2019 No. or %	2019 Amount	2020 No. or %	2020 Amount
Grants within Paylines		805	319,359	933	409,440
	Traditional R01	544	260,317	714	352,832



(Continued from previous page)

Grant Category	R01 or Share	2019 No. or %	2019 Amount	2020 No. or %	2020 Amount
RFA Grants		118	100,779	93	143,328
	Share of Competing Grant Funds	17.6%		21.0%	
Exception Grants		373	253,357	284	271,961
	Share of Competing Grant Funds	44.2%		39.9%	

## COMPETING RPGS

Statistical Measure	2019	2020
<b>Total Competing Application Requests*</b>	<b>10,108</b>	<b>9,538</b>
Funding Success Rate	12%	13%&
Percentile Funding for R01 Grants	8th & 14th	10th & 15th
Average Cost-Competing	\$486	\$503
Average Reduction from Recommended/ Requested Levels	-14%	-14%&

**\*Excludes SBIR/STTR**


The FY 2020 competing RPG average cost calculation includes multi-year funded grants with a 1 year average cost estimation.

FY 2019 figures include FY 2019 Cancer Moonshot funds.

FY 2020 figures include FY 2020 Cancer Moonshot funds.

## RPGs Funding Mechanisms

### Percent Share of Total RPG Funds, FY 20



cancer.gov

The “Other” category includes DP1, DP2, DP5, R00, R15, R50, R56, U01, U19, UG3,UH2, UH3, and UM1 grant activities.

Includes fiscal years 2019 and 2020 Cancer Moonshot funding and excludes all carryover obligations.&

## GRANT FUNDING PAYLINES

RPG Mechanism	2019	2020	Description
R01 Traditional Grants	8th & 14th	10th & 15th	Percentile
P01 Program Projects	19% Reduction	17% Reduction	SPL Selected*
R03 Small Grants	25	25	Impact Score
R15 Academic Research	25	25	Impact Score
R21 Exploratory Phase I	7th	9th	Percentile
R33 Exploratory Phase II	N/A	N/A	SPL Selected*
R41/R42 STTR	22	26	Impact Score
R43/R44 SBIR	29	25	Impact Score

**\*SPL = Scientific Program Leaders (NCI)&**

## RPGs Requested and Awarded

The following table displays requested and awarded RPGs and the success rate for fiscal years 2019 and 2020. These numbers include Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards. The Download the Data link contains data for the prior ten years.

### RPGS REQUESTED, AWARDED, AND SUCCESS RATE

(Dollars in Thousands)

Fiscal Year	Type	Number Requested	Amount Requested	Number Awarded	Amount Awarded	Success Rate
2019	Competing New	10,713	\$4,880,003	1,207	\$545,687	<b>11.9%</b>
	Competing Renewal	445	332,705	122	90,402	
	Competing Supplement	28	7,197	7	1,611	
	<b>Competing Subtotal</b>	<b>11,186</b>	<b>5,219,905</b>	<b>1,336</b>	<b>637,700</b>	
	Non-Competing			3,648	1,903,999	
	<b>FY 2019 RPG Total</b>			<b>4,984</b>	<b>\$2,541,700</b>	
2020	Competing New	10,361	\$4,866,693	1,210	\$595,825	<b>12.4%</b>
	Competing Renewal	463	385,101	136	161,312	
	Competing Supplement	28	7,485	4	885	

(Continued from previous page)

Fiscal Year	Type	Number Requested	Amount Requested	Number Awarded	Amount Awarded	Success Rate
2020	Competing Subtotal	10,852	5,259,279	1,350	758,022	12.4%
	Non-Competing			3,720	2,013,645	
	FY 2020 RPG Total			5,070	\$2,771,666	

**Includes Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) Awards.**

**Success rate is the number of awarded grants divided by the number of awards requested.**

**Fiscal years 2017, 2018, 2019, and 2020 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.**

## RPG Awards by Grant Activity Codes

This table displays awarded research project grants (RPG) data by grant activity code and count. Please visit [NIH Activity Codes](#) for more information on the descriptions.

### RPGS AVERAGE COST, FY 2011-2020

(Dollars in Thousands)

Year	Total No. Awarded	Total Amount	Average Cost
2011	5,019	\$2,088,352	\$416
2012	5,021	\$2,075,295	\$413
2013	4,816	\$1,924,803	\$400
2014	4,814	\$1,939,623	\$403
2015	4,767	\$2,019,308	\$424
2016	4,666	\$2,068,869	\$443
*2017	4,663	\$2,195,184	\$471
*2018	4,780	\$2,366,530	\$495
*2019	4,984	\$2,456,156	\$493
**2020	5,070	\$2,677,206	\$514

**RPG Activity Codes with a "0" count displayed for No. are grants where NCI did not take the grant award count for the funding since NCI was not the Primary IC funding the award.**

**From FY 2017 onward, RFAs will be accounted for in the actual grant mechanism categories under which they fall.**

**\*Fiscal years 2017, 2018, and 2019 and 2020 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.**

**\*\*Fiscal year 2020 includes multi-year funded grants with a 1 year average cost estimation.**

## RPG AWARDS BY GRANT CODES, FY 2018-2019

(Dollars in Thousands)

Grant Code	2019	2018 Amount	2019 Number	2019 Amount
R01	3,195	\$1,425,516	3,316	\$1,555,105
DP1	1	1,161	1	1,197
DP2	0	466	0	0
DP5	3	1,312	0	0
P01	95	179,123	93	187,766
R00	109	26,260	95	23,566
R37	99	43,535	156	71,569
*RFA	0	0	0	0
U01	306	276,369	300	257,018
U19	2	7,593	2	6,335
UH2	7	1,413	7	1,573
R35	142	129,232	154	145,771
R50	81	13,319	96	15,799
UH3	33	18,797	36	20,106
UA5	0	0	0	0
UM1	27	69,816	23	102,669
UG3	8	4,500	8	4,387
R03	121	9,735	119	11,689
R21	447	85,575	387	92,517

(Continued from previous page)

<b>Grant Code</b>	<b>2019</b>	<b>2018 Amount</b>	<b>2019 Number</b>	<b>2019 Amount</b>
R33	38	14,993	37	19,351
R15	23	10,082	22	9,299
R55	0	0	0	0
R56	2	689	1	345
RC2	0	0	0	0
SBIR/STTR	245	136,670	217	151,141
<b>Total</b>	<b>4,984</b>	<b>\$2,456,156</b>	<b>5,070</b>	<b>\$2,677,206</b>

**RPG Activity Codes with a "0" count displayed for No. are grants where NCI did not take the grant award count for the funding since NCI was not the Primary IC funding the award.**

**From FY 2017 onward, RFAs will be accounted for in the actual grant mechanism categories under which they fall.**

**Fiscal years 2017, 2018, and 2019 and 2020 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.**

**Fiscal year 2020 includes multi-year funded grants with a 1 year average cost estimation.**



## Grants to NCI-Designated Cancer Centers

NCI-designated cancer centers are institutions dedicated to research to develop more effective approaches to prevent, diagnose, and treat cancer. [Find an NCI designated cancer center](#) near you and learn about its patient services and research capabilities.

The grant count and amounts include multi-year funded awards and the FY 2020 Cancer Moonshot funds, excludes carryover obligations for fiscal years 2017 through 2019.&

### NCI-DESIGNATED CANCER CENTER TOTALS, FY 2020

*(Dollars in Thousands)*

Mechanism	Count	Amount
<b>*Total P30 Core Grants</b>	71	\$359,302
Planning Grants (P20s)	16	6,194
**Other Cancer Center Grants	0	
<b>Total Cancer Centers</b>	<b>87</b>	<b>\$376,953</b>

**\*Includes multi-year funded awards and FY 2020 Cancer Moonshot funds, excludes carryover obligations for fiscal years 2017 through 2019.**

**\*\*Per the National Institutes of Health's Office of Extramural Research (OER) "Count Rules" & guidelines policy, updated each fiscal year with limits based on the cost center and division; this category is to be reported as zero.**

## NCI-DESIGNATED CANCER CENTERS BY STATE (P30 CORE GRANTS), FY 2020

(Dollars in Thousands)

State	Grantee Institution	Code	Count	Amount
Alabama	University of Alabama at Birmingham	Comprehensive Core	1	\$7,060
Arizona	University of Arizona	Comprehensive Core	1	4,900
California	Beckman Research Institute/City of Hope	Comprehensive Core	1	4,689
	Salk Institute for Biological Studies	Basic Core	1	3,067
	Sanford Burnham Prenys Medical Discovery Institute	Basic Core	1	4,669
	Stanford University	Comprehensive Core	1	3,563
	University of California Davis	Comprehensive Core	1	3,640
	University of California Los Angeles	Comprehensive Core	1	5,592
	University of California San Diego	Comprehensive Core	1	6,453
	University of California San Francisco	Comprehensive Core	1	9,234

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
California	University of California Irvine	Comprehensive Core	1	3,103
	University of Southern California	Comprehensive Core	1	7,601
Colorado	University of Colorado Denver	Comprehensive Core	1	4,603
Connecticut	Yale University	Comprehensive Core	1	4,869
District of Columbia	Georgetown University	Comprehensive Core	1	2,483
Florida	H. Lee Moffitt Cancer Center & Research Institute	Comprehensive Core	1	3,344
	University of Miami School of Medicine	Comprehensive Core	1	3,290
Georgia	Emory University	Comprehensive Core	1	2,624
Hawaii	University of Hawaii at Manoa	Clinical Core	1	2,156
Illinois	Northwestern University at Chicago	Comprehensive Core	1	7,195
	University of Chicago	Comprehensive Core	1	4,887

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Indiana	Indiana Univ- Purdue Univ at Indianapolis	Clinical Core	1	3,443
	Purdue University West Lafayette	Basic Core	1	1,860
Iowa	University of Iowa	Comprehensive Core	1	3,131
Kansas	University of Kansas Medical Center	Clinical Core	1	3,686
Kentucky	University of Kentucky	Clinical Core	1	2,893
Maine	Jackson Laboratory	Basic Core	1	2,335
Maryland	Johns Hopkins University	Comprehensive Core	1	7,818
	University of Maryland Baltimore	Comprehensive Core	1	3,692
Massachusetts	Dana-Farber Cancer Institute	Comprehensive Core	1	12,744
	Massachusetts Institute of Technology	Basic Core	1	3,755

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Michigan	University of Michigan at Ann Arbor	Comprehensive Core	1	8,587
	Wayne State University	Comprehensive Core	1	3,468
Minnesota	Mayo Clinic in Rochester	Comprehensive Core	1	6,651
	University of Minnesota	Comprehensive Core	1	4,396
Missouri	Washington University	Comprehensive Core	1	6,689
Nebraska	University of Nebraska Medical Center	Clinical Core	1	2,107
New Hampshire	Dartmouth College	Comprehensive Core	1	5,037
New Jersey	Rutgers Cancer Institute of New Jersey	Comprehensive Core	1	3,918
New Mexico	University of New Mexico Health Science Center	Comprehensive Core	1	1,374
New York	Albert Einstein College of Medicine Yeshiva University	Clinical Core	1	3,529

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
New York	Cold Spring Harbor Laboratory	Basic Core	1	4,404
	Columbia University Health Sciences	Comprehensive Core	1	5,752
	Ichan School of Medicine at Mount Sinai	Clinical Core	1	3,215
	New York University School of Medicine	Comprehensive Core	1	5,339
	Roswell Park Cancer Institute Corp	Clinical Core	1	5,688
	Memorial Sloan-Kettering Institute for Cancer Res	Comprehensive Core	1	14,569
North Carolina	Duke University	Comprehensive Core	1	6,476
	University of North Carolina Chapel Hill	Comprehensive Core	1	7,854
	Wake Forest University Health Sciences	Comprehensive Core	1	3,684
Ohio	Case Western Reserve University	Comprehensive Core	1	6,008

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Ohio	Ohio State University	Comprehensive Core	1	5,922
Oklahoma	University Of Oklahoma Health Sciences Center	Clinical Core	1	3,773
Oregon	Oregon Health and Science University	Comprehensive Core	1	3,514
Pennsylvania	Research Institute of Fox Chase Cancer Center	Comprehensive Core	1	3,696
	Thomas Jefferson University	Clinical Core	1	3,954
	University of Pennsylvania	Comprehensive Core	1	9,133
	University of Pittsburgh at Pittsburgh	Comprehensive Core	1	6,424
	Wistar Institute	Basic Core	1	2,925
South Carolina	Medical University of South Carolina	Clinical Core	1	2,307
Tennessee	St. Jude Children's Research Hospital	Comprehensive Core	1	7,151
	Vanderbilt University	Comprehensive Core	1	8,031

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Texas	Baylor College of Medicine	Comprehensive Core	1	4,638
	University of Texas Health Science Center	Clinical Core	1	2,658
	University of Texas M.D. Anderson Cancer Center	Comprehensive Core	1	12,313
	University of Texas Southwestern Medical Center	Comprehensive Core	1	2,452
Utah	University of Utah	Comprehensive Core	1	4,858
Virginia	University of Virginia	Clinical Core	1	2,978
	Virginia Commonwealth University	Clinical Core	1	2,655
Washington	Fred Hutchinson Cancer Research Center	Comprehensive Core	1	11,689
Wisconsin	University of Wisconsin-Madison	Comprehensive Core	1	5,104
<b>Total P30 Core Grants</b>			<b>71</b>	<b>359,302</b>



## Specialized Programs of Research Excellence (SPOREs)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). Each SPORE focuses on a specific organ site, such as breast or lung cancer, or on a group of highly related cancers, such as gastrointestinal cancers. SPOREs are designed to enable the rapid and efficient movement of basic scientific findings into clinical settings, as well as to determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer. Total funding shown represents the SPORE program using relevant P50s, P20s, and co-funded grants external to NCI.

The [Translational Research Program \(TRP\)](#) is the home of the SPOREs, a cornerstone of NCI's efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists, and support projects that will result in new and diverse approaches to the prevention, early detection, diagnosis, and treatment of human cancers. For more information on these SPORE grants and organ sites, please visit the [Translational Research Program](#).

The [NCI Funded Research Portfolio \(NFRP\)](#) web site contains additional information about the SPORE grants listed below that have been funded by NCI. The NFRP provides access to various NCI budget reports that contain information about research funding according to specific research categories. For more detailed information on all SPORE grants, please visit the [NCI Funded Research Portfolio](#).

## FY 2020 FUNDING FOR SPORE GRANTS

(Whole Dollars)

Mechanism	Site	Amount
P50 & P20 SPORES	Bladder	2,184,846
	Brain	13,547,868
	Breast	14,553,545
	Cervical	1,704,839
	Endometrial	2,148,436
	Gastrointestinal (GI)	9,300,730
	GI (Colorectal & Pancreatic Cancers)	3,578,951
	Head and Neck	1,125,482
	Kidney	4,728,224
	Leukemia	5,805,346
	Liver	4,626,334
	Lung	9,890,234
	Lymphoma	9,098,036
	Melanoma	4,237,055
	Myeloma	2,349,611
	Neuroendocrine	1,478,968
	Ovarian	7,209,181
Pancreatic	2,184,707	
Prostate	14,499,636	

(Continued from previous page)

Mechanism	Site	Amount
P50 & P20 SPOREs	Sarcoma	2,170,212
	Skin	2,369,171
	<b>Total P50 SPOREs</b>	<b>\$118,791,412</b>
Co-funded	Head & Neck	\$791,200
	<b>Total Co-funded</b>	<b>\$791,200</b>
<b>Total Number of SPOREs, Total SPORE Funding</b>		<b>\$119,582,612</b>


## Dr. Ruth L. Kirschstein National Research Service Awards (NRSA)

This trainee award program is named after Dr. Ruth L. Kirschstein, a polio vaccine researcher and a champion of research training and inclusion of underrepresented individuals in the scientific workforce. Dr. Kirschstein was the first woman to become director of an NIH institute.&

The NCI Ruth L. Kirschstein National Research Service Award (NRSA) program helps ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to meet the Nation’s biomedical, behavioral, and clinical research needs.

### National Research Service Awards (NRSAs) Predoctoral and Postdoctoral Trainees (Full-Time Trainee Positions)

Fiscal Years 2011 - 2020



cancer.gov


Data for fiscal years 2014 and 2015 in previous editions of the NCI Budget Fact Book reported the total number of “Individual” and “Institutional” awards instead of the total number of Predoctoral and Postdoctoral full-time training positions. This table has been updated with the correct data.

## Research Career Awards “K” Program

The NCI career development (K) awards program includes a broad range of funding mechanisms and provides scientists with support to further develop their cancer research careers, transition to independence, expand their existing research programs, or mentor junior investigators. The K awards are a significant component of NCI’s training effort.&

### Total Number of K Awards


Fiscal Years 2011 - 2020



cancer.gov

# Percent of Total Research Career Awards Funded

Fiscal Year 2020



- K00 Post-Doc-Fellow Awards
- K01 Research Scientist Development Award
- K05 Research Scientist Award
- K07 Preventive Oncology
- K08 Clinical Investigator
- K12 Institutional Clinical Oncology Research
- K22 Transitional Career Development
- K23 Patient-Oriented Career
- K24 Patient-Oriented Career - Mid Career
- K25 Mentored Quantitative Research Career Development Award
- K43 Mentored Career Devel/Temin Intl Career
- K99 NIH Pathway to Independence Awards

cancer.gov

## Grant and Contract Awards

The following displays the number and dollar amount of grant and contract awards by state and country with details for institutions receiving more than \$15 million in support from NCI.

**Grants** are used when no substantial programmatic involvement is anticipated between the NCI and the grant recipient during performance of the financially assisted activities and when there is no expectation on the part of the NCI of a specified service or product for NCI.&


**Contracts** are used to procure cancer research services and other resources that the Federal government needs to advance the NCI cancer research mission.

Grant and contract data includes FY 2020 Cancer Moonshot funds and excludes FYs 2017 through 2019 Cancer Moonshot carryover obligations, Breast Cancer Stamp, NRSA tap, the Loan Repayment Program, Program Evaluation, and other assessments. Per the National Institutes of Health's Office of Extramural Research (OER) "Count Rules" & guidelines policy are updated each fiscal year with limits based on the cost center and division. A "0" indicates an award funded by other NIH Institutes that NCI also co-funded.

## Grant and Contract Awards by State and Institution

In the map graphic below, grant and contract awards are presented by state. The table below the graphic provides information for U.S. territories. Within each state, hover to view the total amount awarded and click to view detailed data on institutions that received more than \$15 million in support from NCI during FY 2020. For purposes of the Fact Book, institutions include universities, cancer centers, and hospitals.

# Grant and Contract Awards by State and Institution, FY 2020



Other category represents total grant and contract funding in that state for all remaining organizations including universities, cancer centers, and hospitals who receive less than \$15 million in NCI support.

## GRANT AND CONTRACT AWARDS BY STATE, FY 2020

(Whole Dollars)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Alabama	68	\$44,667,925	3	\$430,000	71	\$45,097,925
Alaska	1	500,651	0	0	1	500,651



(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Arizona	56	36,386,966	2	872,543	58	37,259,509
Arkansas	18	6,821,319	1	383,213	19	7,204,532
California	901	511,810,003	21	23,208,033	922	535,018,036
Colorado	98	39,883,556	4	871,715	102	40,755,271
Connecticut	121	62,430,224	2	3,566,890	123	65,997,114
Delaware	11	8,507,549	0	0	11	8,507,549
District Of Columbia	65	31,809,829	6	5,782,749	71	37,592,578
Florida	195	88,681,302	3	1,868,461	198	90,549,763
Georgia	124	52,897,830	27	7,133,412	151	60,031,242
Hawaii	17	13,119,588	1	1,685,405	18	14,804,993
Idaho	1	86,791	1	511,597	2	598,388
Illinois	248	131,086,577	9	7,335,284	257	138,421,861
Indiana	75	32,834,751	1	121,856	76	32,956,607
Iowa	34	22,992,899	1	4,181,294	35	27,174,193
Kansas	22	11,847,138	0	0	22	11,847,138
Kentucky	48	20,646,373	2	3,326,062	50	23,972,435
Louisiana	31	12,351,448	3	1,963,048	34	14,314,496
Maine	15	10,684,289	0	0	15	10,684,289
Maryland	183	108,767,277	56	640,578,174	239	749,345,451
Massachusetts	713	413,019,240	7	2,288,808	720	415,308,048

(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Michigan	218	110,188,206	0	93,805	218	110,282,011
Minnesota	150	97,085,861	5	1,100,615	155	98,186,476
Mississippi	1	174,129	0	0	1	174,129
Missouri	139	73,424,239	91	12,012,411	230	85,436,650
Montana	4	2,142,882	0	0	4	2,142,882
Nebraska	43	19,206,733	15	731,379	58	19,938,112
Nevada	3	2,237,299	0	0	3	2,237,299
New Hampshire	37	20,921,702	1	400,000	38	21,321,702
New Jersey	68	31,877,988	1	6,129,864	69	38,007,852
New Mexico	26	15,629,275	1	2,597,703	27	18,226,978
New York	807	454,380,486	8	11,170,884	815	465,551,370
North Carolina	283	143,871,852	3	881,032	286	144,752,884
North Dakota	2	437,031	0	0	2	437,031
Ohio	244	126,836,694	1	364,920	245	127,201,614
Oklahoma	34	16,216,510	2	4,112,926	36	20,329,436
Oregon	59	46,932,108	33	1,709,982	92	48,642,090
Pennsylvania	474	321,815,334	31	2,499,775	505	324,315,109
Rhode Island	15	3,497,796	0	0	15	3,497,796
South Carolina	63	32,935,920	0	0	63	32,935,920
South Dakota	3	1,039,369	2	3,986,764	5	5,026,133

(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Tennessee	166	111,564,944	6	5,878,460	172	117,443,404
Texas	523	272,089,090	5	2,837,385	528	274,926,475
Utah	75	32,792,335	3	2,549,539	78	35,341,874
Vermont	7	4,064,637	1	15,000	8	4,079,637
Virginia	103	53,470,365	16	42,342,521	119	95,812,886
Washington	221	155,240,747	3	5,559,755	224	160,800,502
West Virginia	6	2,136,317	0	0	6	2,136,317
Wisconsin	104	68,709,264	2	1,275,685	106	69,984,949
<b>Subtotal</b>	<b>6,923</b>	<b>3,882,752,638</b>	<b>380</b>	<b>814,358,949</b>	<b>7,303</b>	<b>4,697,111,587</b>
Guam	1	1,532,165	0	0	1	1,532,165
Puerto Rico	12	5,929,207	0	0	12	5,929,207
<b>Total</b>	<b>6,936</b>	<b>\$3,890,214,010</b>	<b>380</b>	<b>\$814,358,949</b>	<b>7,316</b>	<b>\$4,704,572,959</b>

## Grant and Contract Awards by Country

NCI funds and co-funds cancer research all over the world. The table below lists number and dollar amount of grant and contract awards by country.

### GRANT AND CONTRACT AWARDS BY COUNTRY, FY 2020

(Whole Dollars)

Country	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Argentina	0	\$45,706	0	\$0	0	\$45,706
Australia	2	2,291,257	0	0	2	2,291,257
Belarus	0	0	1	121,514	1	121,514
Belgium	1	247,046	0	0	1	247,046
Canada	9	10,674,644	1	85,800	10	10,760,444
Costa Rica	0	0	1	8,445,804	1	8,445,804
Denmark	1	194,683	0	0	1	194,683
France	5	3,249,973	0	0	5	3,249,973
Germany	2	1,222,997	0	0	2	1,222,997
India	0	224,969	0	0	0	224,969
Italy	1	277,695	0	0	1	277,695
Jamaica	0	50,000	0	0	0	50,000
Netherlands	1	196,633	0	0	1	196,633
Nigeria	0	170,454	0	0	0	170,454
South Africa	2	313,649	0	0	2	313,649
Sweden	2	438,619	0	0	2	438,619

(Continued from previous page)

Country	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Switzerland	0	414,000	0	0	0	414,000
Tanzania U Rep	0	75,000	0	0	0	75,000
United Kingdom	3	638,838	0	0	3	638,838
Zambia	0	80,028	0	0	0	80,028
<b>Total</b>	<b>29</b>	<b>\$20,806,191</b>	<b>3</b>	<b>\$8,653,118</b>	<b>32</b>	<b>\$29,459,309</b>

# NCI Historical Trends

Established in 1937, the National Cancer Institute (NCI) was among the first Institutes of the National Institutes of Health (NIH). From the outset, NCI served as a scientific cornerstone of the NIH. The following links provide information about the history of NCI appropriations and the Professional Judgment (Bypass) Budget, as well as data on funding trends and staffing levels.


## NCI Professional Judgment Budget, President's Budget and Appropriations

### Professional Judgment Budget, President's Budget and Enacted Appropriations Comparison

This graph displays a historical view of the Professional Judgment Budget, the President's Budget, and the Enacted Appropriations for the NCI from fiscal years 1974 through 2022. The National Cancer Act gives the NCI Director special authority to submit an annual Professional Judgment Budget, sometimes referred to as the "Bypass Budget," directly to the President and Congress. This budget reflects NCI cancer research priorities and identifies areas of potential investment in cancer research. The President's Budget is an annual report prepared by the White House, and in coordination with federal agencies, proposing funding levels for the federal government, including for the NIH and NCI, according to the President's priorities. Congress reviews the Professional Judgment Budget and the President's Budget, and then conducts its own inquiries and hearings to develop and pass an appropriations bill to fund the government. When the bill is signed into law by the President, the Enacted Appropriation levels become available for NCI's cancer research activities.

# Historical Budget Comparison

Fiscal Years 1974 - 2022



- The Professional Judgment Budget was not released in FY 2014, FY 2015, or in FY 2018. To learn more about this authority and view the budget archive, please visit NCI’s About the Annual Plan and Budget Proposal page.
- The FY 2017 and FY 2018 Enacted Appropriated budget includes \$300,000,000 of Cancer Moonshot<sup>SM</sup> funding. \$400,000,000, \$195,000,000, \$195,000,000 of Cancer Moonshot<sup>SM</sup> funding are included in the FY 2019, FY 2020, and FY 2021 Enacted Appropriated levels, respectively. The Professional Judgment Budget also includes \$400,000,000, \$195,000,000 and \$195,000,000 of Cancer Moonshot<sup>SM</sup> funding in fiscal years 2019, 2020 and 2021, respectively.
- The Enacted Appropriation levels do not include potential adjustments such as Rescissions, Sequestrations, Supplemental funding, or Secretary’s Transfers that may have impacted the amount available for NCI expenditure.

## NCI Appropriations

NCI receives its budget from the United States Congress as part of the federal budget process for the Department of Health and Human Services and NIH.

The NCI budget for FY 2020 (October 1, 2019 through September 30, 2020) is \$6.44 billion. During the period from 2010 through 2020, the NCI budget averaged \$5.43 billion per year.

### APPROPRIATIONS OF THE NCI, 1938-2020

(Whole Dollars)

Fiscal Years	Amount	Notes
<b>1938 - 2002</b>	<b>\$52,940,982,220</b>	
2003	4,622,394,000	Prior to reductions in PL 108-7(-\$30,046,000 for the enacted rescission and \$2,000 lapse). Includes \$263,442,000 of AIDS funding.
2004	4,770,519,000	Prior to reductions in PL 108-199(-\$3,136,000 for Labor/HHS/ED rescission; \$28,128,000 for across the board reduction; -\$15,357,000 NIH 1% transfer assessment, and \$5,000 lapse). Includes \$266,975,000 of AIDS funding.
2005	4,865,525,000	Prior to reductions in PL 108-447(\$38,914,000 .8% across the board reduction; -\$1,353,000 for Labor/HHS/ED rescission; -\$30,505,000 NIH 1% transfer assessment, and \$9,000 lapse). Includes \$265,907,000 of AIDS funding.
2006	4,841,774,000	Prior to reductions in PL 109-149 (-\$48,418,000 for Labor/HHS/ED rescission; -\$3,293,000 HHS transfer for CMS activities; -\$42,834,000 NIH 1% transfer for roadmap activities, and \$4,000 lapse). Includes \$253,866,000 of AIDS funding.
2007	4,797,639,000	Prior to reductions in PL 110-5 (-\$5,015,000 NIH transfer for GEI activities, and \$9,000 lapse). Includes \$253,866,000 of AIDS funding.



(Continued from previous page)

Fiscal Years	Amount	Notes
2008	4,890,525,000	Prior to -\$85,437,000 rescission and \$3,091,000 in NIH transfer activities. Includes supplemental appropriation of \$25,559,000. Includes \$258,499,000 of AIDS funding.
2009	4,968,973,000	Prior to reductions in PL 111-8 (-\$2,042,631 NIH transfer for activities, and \$4,000 lapse). Includes \$265,882,000 of AIDS funding.
2010	5,103,388,000	Prior to -\$760,000 HHS Secretary's transfer, -\$4,459,000 in NIH transfer for activities, and \$22,000 lapse. Includes \$272,130,000 of AIDS funding.
2011	5,103,388,000	Prior to -\$44,810,787 rescission and \$472,000 lapse. Includes \$269,953,000 of AIDS funding.
2012	5,081,788,000	Prior to \$9,605,579 rescission, -\$1,445,000 HHS Secretary's transfer, -\$3,342,000 HHS Secretary's transfer for Alzheimer's research, and \$54,000 lapse. Includes \$271,692,000 of AIDS funding.
2013	5,072,183,000	Prior to -\$254,589,000 under sequestration (Budget Control Act, 2011, PL 112-25), -\$10,144,367 rescission, -\$28,044,000 HHS Secretary's transfer and +\$9,714,000 restored from the National Children's Study and National Eye Institute HIV/AIDS funding, and \$106,000 lapse. Includes \$261,550,000 of AIDS funding.
2014	4,923,238,000	Prior to -\$12,359,000 HHS Secretary's transfer, -\$965,000 HHS Secretary's Cybersecurity Transfer (authorized by section 206 of P.L. 113-76), +\$16,180,552 transfer from National Children's Study, and +\$6,307,000 transfer from NIH Office of AIDS Research, and \$33,000 lapse. Includes \$269,212,000 of AIDS funding.

(Continued from previous page)

Fiscal Years	Amount	Notes
2015	4,950,396,000	Prior to +\$2,632,000 transfer from NIH Office of AIDS Research and \$435,000 lapse. Includes \$269,660,000 of AIDS funding.
2016	5,214,701,000	Prior to -\$7,217,390 HHS Secretary's transfer, -\$1,192,000 transfer to NIH Office of AIDS Research, and \$122,000 lapse. Includes \$266,422,000 of AIDS funding.
2017	5,689,329,000	Prior to -\$11,971,000 HHS Secretary's transfer, -\$17,403,000 transfer to NIH Office of AIDS Research, and \$247,000 lapse. Includes \$249,019,000 of AIDS funding and \$300,000,000 of Cancer Moonshot <sup>SM</sup> funding.
2018	5,964,800,000	Prior to -\$13,309,000 HHS Secretary's transfer, -\$7,785,000 transfer to NIH Office of AIDS Research, and \$250,000 lapse. Includes \$241,234,000 of AIDS funding and \$300,000,000 of Cancer Moonshot <sup>SM</sup> funding.
2019	6,143,892,000	Prior to -\$19,730,000 HHS Secretary's transfer, -\$2,874,000 transfer to NIH Office of AIDS Research, and \$252,786 lapse. Includes \$241,979,000 of AIDS funding and \$400,000,000 of Cancer Moonshot <sup>SM</sup> funding.
2020	6,440,442,000	Prior to -\$4,000 transfer to NIH Office of AIDS Research, and \$254,618 lapse. Includes \$241,975,000 of AIDS funding and \$195,000,000 of Cancer Moonshot <sup>SM</sup> funding.
<b>1938 - 2020</b>	<b>\$146,385,876,220</b>	

## NCI Funding Trends

Funding amounts and percentages reflect actual obligations for each fiscal year.

### NCI FUNDING

Funding, FY 2015-2020

(Dollars in Millions)

Mechanism	2016	2017**	2018**	2019**	2020**
<b>Total NCI</b>	<b>\$5,206.2</b>	<b>\$5,636.4</b>	<b>\$5,927.7</b>	<b>\$5,992.3</b>	<b>\$6,383.4</b>
Research Project Grants	2,146.1	2,278.4	2,450.6	2,541.7	2,749.4
Cancer Centers	335.0	313.0	331.4	337.1	382.0
SPOREs	108.2	111.4	115.8	110.7	113.2
Other P50s/P20s	2.8	1.3	0	7.4	7.9
Specialized Centers	99.3	135.6	178.3	200.8	110.7
Clinical Cooperative Groups	221.0	245.3	255.3	290.1	295.6
R&D Contracts	732.3	880.4	825.4	768.1	823.0
Intramural Research	894.5	899.7	945.5	964.9	1,072.6
Other Mechanisms*	666.9	771.2	825.3	771.5	829.0

**\*Other mechanisms includes Research Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.**

**\*\*Fiscal years 2017, 2018, 2019, and 2020 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.**

## PERCENT CHANGE BY MECHANISM

Percent Change by Mechanism, FY 2016-2020

Mechanism	2015 to 2016	2016 to 2017	2017 to 2018	2018 to 2019	2019 to 2020
<b>Total NCI</b>	<b>5.1%</b>	<b>8.3%</b>	<b>5.2%</b>	<b>1.1%</b>	<b>6.5%</b>
Research Project Grants	2.6%	6.2%	7.6%	3.7%	8.2%
Cancer Centers	16.0%	-6.6%	5.9%	1.7%	13.3%
SPOREs	5.4%	3.0%	3.9%	-4.4%	2.3%
Other P50s/P20s	-51.5%	-52.6%	-100.0%	100.0%	6.5%
Specialized Centers	-11.6%	36.5%	31.5%	12.6%	-44.9%
Clinical Cooperative Groups	-11.9%	11.0%	4.1%	13.6%	1.9%
R&D Contracts	22.7%	20.2%	-6.2%	-6.9%	7.1%
Intramural Research	6.1%	0.6%	5.1%	2.1%	11.2%
Other Mechanisms*	1.1%	15.6%	7.0%	-6.5%	7.5%

**\*Other mechanisms includes Research Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.**

**\*\*Fiscal years 2017, 2018, 2019, and 2020 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.**

## PERCENT SHARE OF TOTAL NCI DOLLARS

Mechanism Share of NCI Budget, FY 2016-2020

Mechanism	2016	2017	2018	2019	2020
Research Project Grants	41.2%	40.4%	41.3%	42.4%	43.1%
Cancer Centers	6.4%	5.6%	5.6%	5.6%	6.0%
SPOREs	2.1%	2.0%	2.0%	1.8%	1.8%
Other P50s/P20s	0.1%	0.0%	0.0%	0.1%	0.1%
Specialized Centers	1.9%	2.4%	3.0%	3.4%	1.7%
Clinical Cooperative Groups	4.2%	4.4%	4.3%	4.8%	4.6%
R&D Contracts	14.1%	15.6%	13.9%	12.8%	12.9%
Intramural Research	17.2%	16.0%	16.0%	16.1%	16.8%
Other Mechanisms*	12.8%	13.7%	13.9%	12.9%	13.0%

**\*Other mechanisms includes Research Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.**


**\*\*Fiscal years 2017, 2018, 2019, and 2020 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.**

## Extramural vs Intramural and RMS Funding

The following is a comparison broken out by mechanism and total between Extramural dollars spent vs Intramural Research Program (IRP) and Research Management and Support (RMS).

## Extramural vs Intramural and RMS Funding

Fiscal Years 2016 - 2020



\*Fiscal years 2017, 2018, 2019, and 2020 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.

## FY 2016-2020 TOTAL NCI FUNDING

(Dollars in Millions)

2016	2017*	2018*	2019*	2020*	2016-2020 % Change
\$4,952.6	\$5,206.2	\$5,636.4	\$5,927.7	\$6,383.4	22.6%

**\*Fiscal years 2017, 2018, 2019, and 2020 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.**

## FY 2016-2020 EXTRAMURAL FUNDING

(Dollars in Millions)

Mechanism	2016	2017*	2018*	2019*	2020*	2016-2020 % Change
Research Project Grants	\$2,146.1	\$2,278.4	\$2,450.6	\$2,541.7	\$2,749.4	28.1%
Cancer Centers	335.0	313.0	331.4	337.1	382.0	14.0%
SPOREs	108.2	111.4	115.8	110.7	113.2	4.6%
Other P50s/ P20s	2.8	1.3	0.0	7.4	7.9	182.1%
Other Specialized Centers	99.3	135.6	178.3	200.8	110.7	11.5%
Other Research Grants	399.1	481.9	537.9	506.8	548.1	37.3%
NRSA	73.0	77.6	82.4	87.0	96.4	32.1%
R&D Contract	732.3	880.4	825.4	768.1	823.0	12.4%
Buildings & Facilities	16.0	30.0	18.0	18.0	30.0	87.5%
<b>Total Extramural Funds</b>	<b>\$3,911.9</b>	<b>\$4,309.7</b>	<b>\$4,539.8</b>	<b>\$4,577.5</b>	<b>\$4,860.7</b>	<b>24.3%</b>

\*Fiscal years 2017, 2018, 2019, and 2020 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.

## FY 2016-2020 INTRAMURAL AND RMS FUNDING

(Dollars in Millions)

Mechanism	2016	2017*	2018*	2019*	2020*	2016-2020 % Change
Intramural Research	\$894.5	\$899.7	\$945.5	\$964.9	\$1,072.6	19.9%
RMS	399.8	427.0	442.4	449.9	450.0	12.6%
<b>Total IRP &amp; RMS Funds</b>	<b>\$1,294.3</b>	<b>\$1,326.7</b>	<b>\$1,387.9</b>	<b>\$1,414.8</b>	<b>\$1,522.6</b>	<b>17.6%</b>

\*Fiscal years 2017, 2018, 2019, and 2020 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.



## Comparison of Dollars, Positions, and Space

This page presents tables comparing of NCI’s budget, full-time equivalent (FTE) positions, and occupied space from fiscal years 2011 through 2020.


In this table, funds represent obligations against the annual appropriation in millions of dollars. Fiscal years 2017 through 2020 figures include the Cancer Moonshot<sup>SM</sup> funding. FTEs are the number of work years for appointed employees of the NCI. A work year equals 2,080 hours. Space is in thousands of square feet, excluding NCI-Frederick.

The increase in space (Sq Ft) during FY 2013 is due to NCI’s lease of its Shady Grove complex, a new consolidated facility in Rockville, MD. This facility has the advantage of providing additional space for NCI scientific programs, and includes conference and meeting rooms, a cafeteria, and a data center that serves multiple NCI facilities. During FY 2013, NCI was working to decommission their vacated leased facilities, and continued to lease a portion of them while completing the decommissioning process.

The 2016 FTE count has been updated to include Commissioned Corp staff.

## Comparison of Dollars, Positions, and Space

Fiscal Years 2011 - 2020



cancer.gov

## NCI Personnel

The table below displays NCI-staffing levels, by type of appointment, for fiscal years 2010-2020.

- Full-time equivalents represent 2,080 hours per person employed
- Full-time and part-time appointments include employees from NIH Employment Report 71E
- Training Fellows including visiting fellows, Cancer Research Training Award (CRTA) and the few remaining Intramural Research Training Award (IRTA), biotech, and tech transfers
- Total employees include full-time and part-time permanent tours


### NCI PERSONNEL, FY 2009-2019

Fiscal Year	Full Time Permanent	Other Than Full Time Permanent	Training Fellows	Total Personnel Resources
2010	2,148	1,011	1,073	4,232
2011	2,180	1,029	1,108	4,317
2012	2,139	997	906	4,042
2013	2,173	948	847	3,968
2014	2,139	923	879	3,941
2015	2,119	897	947	3,963
2016	2,050	1,001	972	4,023
2017	2,156	890	1,042	4,088
2018	2,083	845	1,045	3,973
2019	2,101	879	1,061	4,041
2020	2,110	883	1,150	4,143

## NCI and NIH AIDS Funding History

The NCI has played a major role in HIV/AIDS research since the beginning of the AIDS epidemic. Scientists within and supported by the NCI have made a number of key discoveries. HIV/AIDS research is conducted throughout the Divisions and Offices of the NCI and is coordinated by the [NCI Office of HIV and AIDS Malignancy](#).

In addition, because HIV/AIDS transcends every area of clinical medicine and basic scientific investigation, the NIH AIDS research effort involves every NIH Institute and Center. The NIH Office of AIDS Research has primary responsibility for planning and coordinating AIDS research across the NIH.



# Cancer Moonshot<sup>SM</sup> - Recent Fiscal Year Funding

The 21st Century Cures Act, which was signed into law in December 2016, authorized \$1.8 billion to fund the Cancer Moonshot over a 7 year period. The goal of the Cancer Moonshot is to accelerate progress in cancer, including prevention and screening, from cutting edge basic research to wider uptake of standard of care.

The following pages contain information on the \$195 million of Cancer Moonshot funding received during Fiscal Year 2020.

More information on Cancer Moonshot can be found by visiting the [NCI Cancer Moonshot Initiative page](#).

Information on recent funding opportunity announcements can be found on the [Cancer Moonshot Funding Opportunities page](#).

## CANCER MOONSHOT FISCAL YEAR SUMMARY

*(Whole Dollars)*

Fiscal Year	Authorization
2017	\$300,000,000
2018	\$300,000,000
2019	\$400,000,000
2020	\$195,000,000
2021	\$195,000,000
2022	\$194,000,000
2023	\$216,000,000
<b>Total</b>	<b>\$1,800,000,000</b>


Funding for the Cancer Moonshot is appropriated on an annual basis. The following pages contain information on the initial \$195 million of Cancer Moonshot funding received during Fiscal Year 2020.

## Cancer Moonshot<sup>SM</sup> - Obligations by Budget Mechanism

With over \$330 million appropriated for Cancer Moonshot activities in fiscal year (FY) 2020, funding was allocated into four budget mechanisms: research grants, R&D contracts, intramural research, and research management and support, as shown in the chart below.

### FY 2020 Cancer Moonshot and Carryover - Obligations by Mechanism

Fiscal Year 2020



cancer.gov

Similar to the institute's annual appropriation, NCI reports Cancer Moonshot obligations by funding mechanism.

## FY 2020 CANCER MOONSHOT AND CARRYOVER - OBLIGATIONS BY MECHANISM

(Whole Dollars)

Type of Mechanism	Mechanism	Number	Amount <sup>1</sup>
Research Project Grants (RPGs)	Competing	19	\$22,646,286
	Noncompeting	40	\$35,416,673
	Administrative Supplements	7	\$1,055,479
	<b>Subtotal, without SBIR</b>	<b>59</b>	<b>\$59,118,438</b>
	SBIR/STTR Grants	2	\$756,262
	<b>Subtotal, RPGs</b>	<b>61</b>	<b>\$59,874,700</b>
Centers	Cancer Centers Grants- P30s	0	\$10,708,014
	P50s	7	\$8,574,768
	Cooperative Agreements-U54s/U41s	14	\$12,914,610
	<b>Subtotal, Centers</b>	<b>21</b>	<b>\$32,197,392</b>
Other Research	Resource Grants-U24s/ U2Cs	11	\$23,516,062
	<b>Subtotal, Other Research</b>	<b>11</b>	<b>\$23,516,062</b>
<b>Subtotal, Research Grants</b>		<b>93</b>	<b>\$115,588,154</b>
Intramural Research	Program	0	\$17,469,326
Research Management & Support	RMS	0	\$87,434

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount <sup>1</sup>
R&D Contracts	R&D Contracts	9	\$26,256,370
	SBIR/STTR Contracts	4	\$5,378,046
	<b>Subtotal, R&amp;D Contracts</b>	<b>13</b>	<b>\$31,634,416</b>
<b>Total</b>			<b>\$164,779,329</b>

<sup>1</sup> Includes new obligations and recoveries from fiscal years 2017, 2018, and 2019 carryover accounts.

## Cancer Moonshot<sup>SM</sup> - Funding by Research Category

To ensure the Cancer Moonshot goals and approaches were grounded in the best science, NCI convened a [Blue Ribbon Panel](#) (BRP) of scientific experts as a working group to the National Cancer Advisory board. In September of 2016, the BRP presented a [final report](#) outlining 10 research recommendations that represent areas that are well-positioned to accelerate progress in cancer prevention, diagnosis, treatment and care.

The following research categories align with these 10 recommendations:

### CANCER MOONSHOT BY CATEGORY, FY 2020

(Whole Dollars)

Research Category	Amount <sup>1</sup>
Network for Direct Patient Engagement	\$16,232,008
Cancer Immunotherapy Translational Science Network	\$27,775,428
Therapeutic Target Identification to Overcome Drug Resistance	\$10,826,093
A National Cancer Data Ecosystem for Sharing and Analysis	\$10,780,075
Fusion Oncoproteins in Childhood Cancers	\$1,651,795
Minimize Cancer Treatment's Debilitating Side Effects	\$10,837,064
Prevention and early detection: Implementation of Evidence-Based Approaches	\$55,447,546
Retrospective Analysis of Biospecimens from Patients Treated with Standard of Care	\$55
Generation of Human Tumor Atlases	\$14,949,477
Development of New Enabling Cancer Technologies	\$16,154,726



(Continued from previous page)

Research Category	Amount <sup>1</sup>
Other Cancer Moonshot priority activities (e.g., Partnership for Accelerating Cancer Therapies)	\$125,064
<b>Total</b>	<b>\$164,779,329</b>

<sup>1</sup> Includes new obligations and recoveries from fiscal years 2017, 2018, and 2019 carryover accounts.



**NATIONAL  
CANCER  
INSTITUTE**

cancer.